Result of Annual General Meeting

RNS Number : 9334S
Redx Pharma plc
14 March 2023
 

REDX PHARMA PLC

("Redx" or "the Company")

 

Result of Annual General Meeting


Alderley Park, UK, 14 March 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease announces that its Annual General Meeting was held at 11am on 14 March 2023, with all resolutions passed by substantial majorities.

 

The table below sets out the details of the votes put to shareholders

 

Resolution number

Resolution name

Number of votes for & discretionary

% of votes for & discretionary

Number of votes against

% of votes against

% of votes withheld*

Total votes cast (including withheld)

1

Receive the Company's annual accounts

306,243,523

94.91%

16,434,331

5.09%

0.00%

322,680,605

2

Re-appoint Ernst & Young as auditors

322,677,854

100.00%

2,751

0.00%

0.00%

322,680,605

3

Re-elect Dr Bernhard Kirschbaum as a director

306,241,648

94.91%

16,436,206

5.09%

0.00%

322,680,605

4

Re-elect Lisa Anson as a director

322,678,730

100.00%

1,875

0.00%

0.00%

322,680,605

5

Re-elect Natalie Berner as a director

322,673,730

100.00%

6,875

0.00%

0.00%

322,680,605

6

Authorise the directors to allot shares

322,551,347

99.96%

125,732

0.04%

0.00%

322,680,605

7

Disapply pre-emption rights

322,545,847

99.96%

133,983

0.04%

0.00%

322,680,605

*A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes 'For' or 'Against'

 

For further information, please contact:



 




 

Redx Pharma Plc

UK Headquarters

Caitlin Pearson, Head of Communications 

ir@redxpharma.com

 

Lisa Anson, Chief Executive Officer

T: +44 (0)1625 469 918

 

US Office

Peter Collum, Chief Financial Officer



 

SPARK Advisory Partners (Nominated Adviser)

T: +44 (0)203 368 3550

Matt Davis/ Adam Dawes




WG Partners LLP (Joint Broker)

T: +44 (0)203 705 9330

Claes Spång/ Satheesh Nadarajah/ David Wilson




Panmure Gordon (UK) Limited (Joint Broker)

T: +44 (0)207 886 2500

Rupert Dearden/ Freddy Crossley/ Emma Earl




FTI Consulting

T: +44 (0)203 727 1000

Simon Conway/ Ciara Martin







 

About Redx Pharma Plc

 

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. The Company's lead fibrosis product candidate, the selective ROCK2 inhibitor RXC007, is in development for interstitial lung disease and commenced a Phase 2a trial for idiopathic pulmonary fibrosis (IPF) in October 2022, with topline data expected in Q1 2024. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, being developed as a targeted treatment for Wnt-ligand dependent cancers, is expected to report both monotherapy and combination with anti-PD-1 Phase 2 data during 2023.  Redx's third drug candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is progressing towards a CTA/IND application at the end of 2023. 

 

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a non-covalent (reversible) BTK inhibitor now approved by the US FDA for adult patients with mantle cell lymphoma previously treated with a covalent BTK inhibitor, and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic diseases including IPF, which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a pan-RAF inhibitor developed by Redx which Jazz is now progressing through Phase 1 clinical studies, and an early stage oncology research collaboration. 

 

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/  

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGDZGMFMDMGFZM

Companies

Redx Pharma (REDX)
UK 100

Latest directors dealings